文献速递药物相互作用治疗药物监测与药物基因组学特殊人群用药

HIV感染者与精神科人群艾司西酞普兰群体药代动力学及药物相互作用与靶标 attainment 概率

Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-07

该研究基于39例HIV感染者和71例未感染精神科患者的159份血药浓度,建立艾司西酞普兰群体药代动力学模型,发现其清除率与分布容积分别为23.1 L/h和920 L,HIV感染及抗逆转录病毒治疗不影响处置,质子泵抑制剂合用使清除率降低19%,标准10 mg每日一次方案下56%患者可能暴露不足。

要点

  • HIV感染及抗逆转录病毒治疗(含增强方案)不改变艾司西酞普兰处置,无需预先剂量调整。
  • 合用质子泵抑制剂使艾司西酞普兰清除率降低19%,临床相关性有限。
  • 标准10 mg每日一次方案下56%患者可能暴露不足,疗效不佳时可考虑治疗药物监测指导个体化给药。

核心结论

  • 艾司西酞普兰处置个体间变异大,人口学、临床和环境协变量解释能力有限,疗效不佳时建议基于治疗药物监测进行剂量个体化。
  • HIV感染及抗逆转录病毒治疗对艾司西酞普兰处置影响轻微,无需预先剂量调整。

研究设计与样本

  • 采用NONMEM进行群体药代动力学分析,共纳入39例HIV感染者和71例未感染精神科患者的159份血浆浓度测量值。
  • 考察年龄、体重、性别、HIV与精神科队列、外消旋西酞普兰治疗及合并用药对口服清除率的影响,并通过模拟计算暴露不足或过度的患者比例。

主要发现

  • 艾司西酞普兰平均清除率为23.1 L/h(个体间变异51%),分布容积为920 L。
  • HIV感染与未感染患者间艾司西酞普兰处置无差异,且不受抗逆转录病毒治疗影响。
  • 合用至少一种质子泵抑制剂(CYP2C19抑制剂)使艾司西酞普兰清除率降低19%,临床相关性有限。
  • 基于模型的模拟显示,标准10 mg每日一次方案下,56%的患者可能暴露不足。

关键数值与推荐

  • 艾司西酞普兰既定治疗目标范围为15-80 ng/mL。
  • 标准方案为10 mg每日一次。

临床怎么用

  • HIV感染者接受抗逆转录病毒治疗(包括增强方案)时,无需对艾司西酞普兰进行预先剂量调整。
  • 合用质子泵抑制剂时无需常规调整艾司西酞普兰剂量,但需关注临床反应。
  • 临床疗效不佳时,可考虑通过治疗药物监测指导艾司西酞普兰剂量个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen. METHODS: A population pharmacokinetic analysis was performed using NONMEM. A total of 159 plasma concentration measurements were obtained from 39 human immunodeficiency virus (HIV)-infected and 71 uninfected psychiatric patients. The influence of age, weight, sex, HIV and psychiatric cohorts, racemic citalopram treatment, and comedications on oral clearance was examined. Simulations served to calculate the percentage of patients expected to be under- or over-exposed, considering established therapeutic targets (15-80 ng/mL). RESULTS: A 1-compartment model with first-order absorption and elimination described the data adequately. The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively. Escitalopram disposition did not differ between HIV-infected and uninfected patients, and was not affected by antiretroviral treatments. Coadministration of at least 1 proton-pump inhibitor (CYP2C19 inhibitor) modestly influenced escitalopram elimination (clearance decreased by 19%), with limited clinical relevance. Model-based simulations showed that, under a standard regimen of 10 mg once daily, a significant proportion of patients (56%) might be under-exposed. CONCLUSION: The variability in escitalopram disposition is large and poorly explained by demographic, clinical and environmental covariates, thus suggesting a role for dosage individualization based on therapeutic drug monitoring in case of poor clinical response. Escitalopram disposition is modestly impacted by comedications and therefore no a priori dosage adjustments are needed in patients receiving antiretroviral treatments, including boosted regimens.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Courlet P, Guidi M, Glatard A, et al. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Br J Clin Pharmacol. 2019. PMID: 31144347. doi:10.1111/bcp.13994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。